Last reviewed 2026-04-22 · How we verify

Drug：Cisplatin

Cisplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing DNA replication and transcription, thereby inducing cancer cell death.

Cisplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing DNA replication and transcription, thereby inducing cancer cell death. Used for Metastatic testicular cancer, Metastatic ovarian cancer, Advanced bladder cancer.

At a glance

Mechanism of action

Cisplatin binds to DNA and forms intrastrand and interstrand crosslinks, which distort the DNA helix and block DNA synthesis and repair mechanisms. This leads to apoptosis in rapidly dividing cancer cells. The drug is non-cell-cycle specific but most effective against cells in S and G2 phases.

Approved indications

• Metastatic testicular cancer
• Metastatic ovarian cancer
• Advanced bladder cancer
• Head and neck cancer
• Non-small cell lung cancer
• Gastric cancer

Common side effects

• Nephrotoxicity
• Ototoxicity
• Nausea and vomiting
• Myelosuppression (thrombocytopenia)
• Myelosuppression (leukopenia)
• Peripheral neuropathy
• Anemia
• Electrolyte abnormalities (hypomagnesemia)

Key clinical trials

• 2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma (PHASE3)
• Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell Carcinoma (EARLY_PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Drug：Cisplatin CI brief — competitive landscape report
• Drug：Cisplatin updates RSS · CI watch RSS
• Sun Yat-sen University portfolio CI